Please login to the form below
Actelion
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Actelion's 2013 sales performance.
Azafaros expands executive team with three senior hires
Prior to this, he held global clinical development and medical affairs leadership roles at Actelion Pharmaceuticals.
J&J aims for US approval of MS drug ponesimod
J&J acquired the S1P receptor modulator as part its $30bn takeover of Actelion, with the FDA application based on the head-to-head phase 3 OPTIMUM study comparing ponesimod to
The mission matters
In the words of Jane Griffiths, Global Head of Actelion, this social contract makes our industry uniquely ‘emotionally salient’ and this salience makes the contract fragile.
Darwinian leadership in the life sciences industry
But it is also because, as Actelion’s Jane Griffith’s said, we touch almost everybody at some point in their lives.
J&J’s ponesimiod tops Aubagio in head-to-head MS trial
Ponesimod, a S1P receptor modulator acquired as part of J&J’s $30bn acquisition of Actelion in 2017, achieved a statistically significant 30.5% reduction in the annualised relapse rate (ARR)
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Gilead agrees $21bn buyout of Immunomedics
- 20 for 2020 – Five pharma companies to watch
- FDA approves Roche’s Actemra COVID-19 trial
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- FDA hands BMS and bluebird bio a priority review for ide-cel
- Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Could formulary intelligence be your brand differentiator?
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Porterhouse Medical strengthens its senior management team
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Could formulary intelligence be your brand differentiator?
- Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
Quick links
Infographics
